Siwei (Shanghai) Biotechnology Co., Ltd.

Patients

Stemirna has started investigator-initiated trials with three top-tier hospitals in China to test the safety and efficacy of mRNA-based personalized cancer vaccine. We are working with the primary investigators at the hospitals to improve treatment plans.

About Us
- Our Story
- News Updates
- Contact Us
Platforms
- mRNA Synthesis Platform
- LPP Delivery Platform
- GMP Manufacturing
Pipeline
- Therapeutic Areas
- Development Candidates
Patients
- Clinical Trials
Partnering
- Investors
Join Us
- Opportunities